Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT07049575

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07049575. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Study identification

NCT ID: NCT07049575
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Incyte Corporation; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Hidradenitis Suppurativa

Interventions

Ruxolitinib Cream Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 3, 2025 (Actual)
Primary completion: Dec 9, 2026 (Estimated)
Completion: Dec 9, 2026 (Estimated)
Last update posted: Oct 9, 2026

2025 – 2026

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
Saguaro Dermatology	Phoenix	Arizona	85008	Recruiting
First Oc Dermatology	Fountain Valley	California	92708	Completed
Amicis Research Center Valencia	Northridge	California	91324	Recruiting
Children'S Hospital of Orange County	Orange	California	92868	Recruiting
Clinical Trials Research Institute	Thousand Oaks	California	91320	Recruiting
Clarity Dermatology	Castle Rock	Colorado	80109	Completed
International Clinical Research Tennessee Llc	Sanford	Florida	32771	Recruiting
Lenus Research Medical Group, Llc	Sweetwater	Florida	33172	Recruiting
Trueblue Clinical Research	Tampa	Florida	33609	Recruiting
Lane Dermatology and Dermatologic Surgery	Columbus	Georgia	31904	Recruiting
Options Research Group, Llc	West Lafayette	Indiana	47906	Recruiting
Equity Medical, Llc	Bowling Green	Kentucky	42104	Recruiting
Delricht Research	Baton Rouge	Louisiana	70809	Recruiting
Revival Research Institute, Llc Troy	Troy	Michigan	48084	Completed
Red River Research Partners	Bolivar	Missouri	65613	Recruiting
Dr Bobby Buka, Md Greenwich Village	New York	New York	10012-1354	Recruiting
Equity Medical, Llc	New York	New York	10019	Recruiting
Red River Research Partners	Fargo	North Dakota	58103	Recruiting
Centricity Research Columbus	Columbus	Ohio	43213	Completed
Unity Clinical Research	Oklahoma City	Oklahoma	73118	Recruiting
Paddington Testing Co Inc	Philadelphia	Pennsylvania	19103	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07049575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 9, 2026 · Synced Nov 12, 2026